Pharmacelsus News Blog


Pharmacelsus Newsletter 09/2015

September 22, 2015

Introduction of a new assay  for the determination of nuclear uptake of  untagged test items.

Pharmacelsus has established a new test system for the quantification of non-labelled test items localized in the nucleus. In a pilot study in HEK293 cells, the test item was successfully identified and quantified in both nuclear and cytosolic fractions. The assay design is applicable to mammalian cell lines, primary cells and fresh tissue. Quantification method is based on LC-MS/MS.
A method sheet on the pilot study of this new assay for nuclear uptake can be downloaded here.
We would be happy to perform this testing with your individual cell line or tissue. Please contact us for your individual study.

Governor Gary R. Herbert visits Pharmacelsus

June 17, 2015

Last week a delegation from Utah (USA) led by Governor Gary R. Herbert visited the Saarland as part of their Europe tour. Since 2002 a treaty exists between both federal states, promising mutual support on economic issues.
On Friday, June 12th, Gary R. Herbert and members of his delegation visited Pharmacelsus. CEO Dr. Christine Batzl-Hartmann introduced the company and its operations.


Dr. Christine Batzl-Hartmann and Gary R. Herbert. Photo: Pharmacelsus


Gouverneur Gary R. Herbert zu Besuch bei Pharmacelsus

Am Freitag, 12. Juni, besuchte Gary R. Herbert mit einigen Mitgliedern seiner Delegation auch Pharmacelsus. CEO Dr. Christine Batzl-Hartmann stellte die Firma und ihre Arbeit vor.


Visiting Israel

Statement of GLP compliance to be renewed after inspection by national authorities in May 2015

June 16, 2015

On May 6th and 7th 2015 Pharmacelsus was inspected by national GLP authorities as part of the periodically conducted GLP inspections. Pharmacelsus is thrilled to announce that the statement of GLP compliance will be renewed for 2015.

Pharmacelsus filed for recertification of GLP compliance in category 8 (bioanalytics) and 9 (pharmacokinetic, pharmacodynamic, pharmacological and metabolical assays in vitro and in vivo as well as toxicological assays in vitro).


Visiting Israel

Pharmacelsus Newsletter 06/2015

June 10, 2015

New Newsletter on Services for Biologicals available

Besides our core expertise for small molecules, Pharmacelsus additionally offers bioavailability and safety studies for  biologicals, e.g. for monoclonal antibodies, small molecule-antibody conjugates, cytokines, growth factors, receptors etc. An overview on our services for biologicals can be downloaded in a PDF document.

Pharmacelsus provides cell-based studies as well as bioanalytical services e.g. the performance of ELISA (non-GLP and GLP) or the development of individual ELISA design, and offers additional services for biologicals and biomarkers within the scope of in vivo PK studies (e.g. checking for infusion reactions).

We are looking forward to your specific biological challenge!


Pharmacelsus Newsletter 03/2015

March 27, 2015

Newsletter on Services for Biomarkers available

Reliable biomarkers are crucial in drug development and clinical trials to determine pharmacological efficacy. Using both antibody-based assays suitable for multiplexing (Luminex, FACS, ELISA) as well as LC-HRMS technology, Pharmacelsus established new methods for quantifying new biomarkers. Please refer to our current 2-page flyer (pdf) on biomarker analysis for examples. 


Visiting Israel

Pharmacelsus Newsletter 02/2015

February 6, 2015

OECD reports outcome of a study in which Pharmacelsus participated as the leading lab:

OECD website (PDF) and the new validated method was submitted to the OECD for a test guideline


Visiting Israel

Merry Christmas and a Happy New Year

December 2014

The entire team at Pharmacelsus wishes you, your company and your families a Merry Christmas and the very best for the New Year.


  • Visiting Israel

Die richtige Dosis

November 11, 2014

Den ganzen Artikel gibt es hier.

  • Visiting Israel

Pharmacelsus ist Teil des ZIM Netzwerk

October 20, 2014

Mehr Informationen zu dem Netzwerk gibt es hier: Pressemitteilung.

Visiting Israel

October 15, 2014

Visiting Israel

October 10, 2014

Motivation for the seminar was the fact that regulatory authorities continue to grow the preclinical testing requirements. Most academic groups, however, fall short of understanding, which experiments they could perform in their own labs and which ones they better outsource to experts.

Therefore, main focus of the seminar was to shed light into preclinical testing requirements and provide the attendees  with hands-on experience. The seminar summarized relevant FDA and EMA guidelines, touched all preclinical areas, and finally provided the audience with an overall strategy how they could advance their projects. The seminar was well received and subsequent seminars have been requested.

If you like to learn more about the seminar, please log in and download the PDF of the presentation.


Presentation in Berlin

September 22, 2014

here to see the invitation.


Visiting Israel

Pharmacelsus Newsletter 09/2014

September 5, 2014

The second issue of the Pharmacelsus Newsletter


Pharmacelsus Newsletter 04/2014

April 10, 2014

The first issue of the Pharmacelsus Newsletter in 2014 is available: This time we introduce our in vitro toxicology service portfolio highlighting the challenges of metabolic toxicity. Included is a link to our recent White Paper (Metabolite Toxicity A Sensitive in vitro Tool For The Detection of Metabolite-Induced Toxicity

Pharmacelsus applies and validates LC-MS/(MS) analysis for phyto-pharmaceuticals

March 28, 2014

A herbal extract may contain more than hundred of different secondary metabolites of differing chemical nature. Pharmacelsus is one of the few bioanalytical laboratories which is applying and validating LC-MS/(MS) techniques in the qualitative and quantitative analysis of herbal extracts, as shown in a new case study focusing on components of Gentian root extract. For further information, please click here (Pharmacelsus applies and validates LC-MS/(MS) analysis for phyto-pharmaceuticals).

CYP inhibition in human liver microsomes - Ki determination

March 21, 2014

here (CYP inhibition in human liver microsomes -Ki determination).

Press Release 02/2014

February 7, 2014

Pharmacelsus and Insilico Biotechnology join forces to deliver combined solutions in preclinical drug development. Integrated platform rationalizes and accelerates the testing and selection of novel Active Pharmaceutical Ingredients (APIs). For further information, please click here to view the press release and here to download the method description.

Pharmacelsus Newsletter 11/2013

November 29, 2013

The fifth issue of the Pharmacelsus Newsletter in 2013 is available:
This time we discuss the challenges of analyzing multiple analytes in newly set-up assays which require highest analytical sensitivity due to low cell numbers and small incubation volumes.

New bioanalytical services available: CYP probe and bile acid cocktail analysis

November 26, 2013

Pharmacelsus has developed new bioanalytical solutions to study drug-related effects on liver functions: Our bioanalytical lab now offers a rapid, highly-sensitive and cost-efficient method to analyse fourteen major bile acids in a single sample, allowing the generation of a comprehensive bile acid profile in plasma or in vitro samples. In addition we have developed a reliable and swift protocol for the multi-probe analysis of CYP activities, including eight major FDA- and EMA-recommended probes. Both methods support analysis of liver functions in particular in systems with low production rates, such as in vitro microtissues.

Pharmacelsus gets involved in antifungal research: new FP7 project "NOFUN - Novel antifungals against resistant organisms"

November 7, 2013

The aim of the 3 year-funded collaborative project is the development of new antifungals against species, such as Aspergillus, Candida, Cryptococcus or Pneumocystis which manifest an increasing resistance towards antifungal agents available on the market. Three SMEs (F2G, UK; OnTarget Chemistry, Sweden and Pharmacelsus, Germany) and two academic partners (University of Manchester, UK and University Rovira I Virgili, Spain) combine their expertise in medicinal chemistry and preclinical research to deliver several drug candidates suitable for clinical development. 

More information available at


Service portfolio of Pharmacelsus: new brochure summarising studies and assays is available

October 17, 2013

15/10/2013: The brochure includes services in the area of ADME & in vitro Pharmacology, Drug Transporter Assays, Pharmacokinetics & in vivo Pharmacology, Indication Specific Assays, Bioanalysis,  Bioanalysis GLP, in vitro Toxicology & Compound Profiling. Available as free download here or ask us to send you your personal copy. 

Pharmacelsus presented at the Insphero Webinar addressing the use of 3D human micro tissue for CYP induction and bile acid analysis

October 08, 2013

24/09/2013: The Insphero 3D primary human hepatocyte cultures - 3D human liver micro tissues - are very versatile and can be utilised of in many drug discovery / drug development studies. In this webinar we presented data on CYP induction studies and bile acid analysis in 3D human liver micro tissue  (PDF).

- Metabolic activity testing with human liver micro tissues

- Application of substrate turnover assays for CYP-induction studies


Pharmacelsus presented at the Insphero User Group Meeting in Boston

September 30, 2013



September 24, 2013

Kleinblittersdorf, Germany, 30/08/2013:

arbecues and other relaxing outside activities in the future.

Pharmacelsus Newsletter 09/2013

September 23, 2013

The fourth issue of the Pharmacelsus Newsletter

  • Visiting Israel


July 5, 2013

The Group of 70 delegates coming from start-up companies in the field of information technology, biotechnology, medical engineering and creative industry, made use of the unique opportunity to strengthen the economic relationship between Israel and Germany.


Pharmacelsus Newsletter 07/2013

July 5, 2013

The third issue of the Pharmacelsus Newsletter in 2013 is available! Pharmacelsus has recently expanded its portfolio of in vivo models and conducted a pilot study for the assessment of metabolomic biomarkers in a rat model of liver fibrosis in collaboration with BIOCRATES Life Sciences, Innsbruck, Austria.


May 29, 2013

Pharmacelsus participates in the UGM of Insphero AG  in order to present its experience with novel 3D cell culture systems, specifically human liver microtissues for drug safety testing. Pharmacelsus overall goal is to improve the in vitro prediction of drug-drug interactions, identification of reactive metabolites and cytochrom P450 profiling using the novel 3d culture system of human liver microtissues. Pharmacelsus will use its strong expertise in drug metabolism models to develop a predictive, highly sensitive in vitro system for the detection of hazardous drug effects and benchmark it against conventional 2D systems using human primary hepatocytes or HepaRG cells.

Pharmacelsus Newsletter 04/2013

April 15, 2013

The second issue of the Pharmacelsus Newsletter in 2013 sheds light on how to elucidate unpredicted mitochondrial toxicity which poses an underestimated risk for late-stage drug attrition.

Pharmacelsus announces its participation in the new European R&D project "WispATDrug"

April 11, 2013

Pharmacelsus annonces its participation in the new multi-national R&D project "WispATDrug" (acronyme for Lead optimization for innovative orally bioavailable wide spectrum antitumor drugs). Press release

Pharmacelsus Newsletter 02/2013

February 18, 2013

The first issue of the Pharmacelsus Newsletter in 2013 presents two crucial methods to determine the binding of your drug to proteins as well as to cellular macromolecules.

Pharmacelsus Newsletter 12/2012

December 18, 2012

The 5th issue of the Pharmacelsus Newsletter gives an overview on preclinical testings required by the regulatory agencies.


Pharmacelsus congratulates its team member

December 12, 2012

Pharmacelsus congratulates its team member Mrs. A. Dressel to be one of the best trainees of the Saarland / Germany in 2011.  


Important info for our Portuguese Customers: Pharmacelsus recognized as R&D entity for SIFIDE system!

November 08, 2012

We are pleased to announce to our customers and R&D partners that Pharmacelsus has been recognized as a R&D entity in the SIFIDE system (System of Incentives for Business Research and Development).

Companies established in Portugal are allowed to perceive a tax credit for R&D activities outsourced to accredited R&D service providers like Pharmacelsus.

Further information on the Portuguese R&D tax credit is available on the website of SIFIDE.


Important info for our French Customers: Pharmacelsus accredited for the French R&D Tax Credit!

October 19, 2012

Companies established in France and active in R&D are allowed to perceive a tax credit for R&D services outsourced to accredited R&D service providers like Pharmacelsus.
Further information on the French R&D tax credit is available on the website of the French Ministry of higher Education and Research.

Patzelt 2012


September 18, 2012

Every year, the commission evaluates small and medium-sized companies with an above-average growth. The performance of the participating companies is rated in five competition categories.
Pharmacelsus cordially thanks its more than 120 satisfied customers in the pharmaceutical and biotechnology industry as well as in academia for having considerably contributed to this success story.

Oskar-Patzelt Stiftung

Video on Youtube

Pharmacelsus Newsletter 08/2012

August 24, 2012

The 4th issue of the Pharmacelsus Newsletter presents a new service: The Dried Blood Spot (DBS) pharmacokinetic investigation is an alternative to traditional plasma PK studies.

Pharmacelsus spotlight logo

Pharmacelsus Spotlight - On the spot for our customers

July 20, 2012

Pharmacelsus presents the first issue of its customer journal Spotlight!

In order to keep you informed about the current status and ongoing developments in the field of pre-clinical research, Pharmacelsus scientists are covering particular topics of pre-clinical drug development in each issue!

We would also like to give you a personal insight into Pharmacelsus and its people: Spotlight will continuously introduce one of our departments and the people working there.

Please contact us to get a free copy!

Health - Made in Germany

June 25, 2012

The German Federal Ministry of Economics and Technology has released a "Guide to Contract Research in Germany".

Health made in Germany

Newsletter and New Whitepaper Available

June 4, 2012

The third issue of the Pharmacelsus Newsletter sheds a light on how in vitro prediction of acute toxicity in animals can save time and costs in regulatory required in vivo toxicity tests.

The whitepaper highlights the usefulness of the in vitro cytotoxicity
testing and the calculation of the in vivo LD50 in preclinical drug screening.

Dr. Christine Batzl-Hartmann (CEO) on European Commission's event in Brussels

June 1, 2012

Dr. Christine Batzl-Hartmann attendet the European Commissions' "Open Information Day and Brokerage Event" in Brussels on May 29, 2012. A video of her presentation can be found here.


May 31, 2012

Pharmacelsus in "transkript" article (PDF).

Patzelt 2012

Pharmacelsus nominated for a business price

May 25, 2012

Pharmacelsus Success Stories now available

May 8, 2012

Two new success stories available.

Pharmacelsus' new whitepaper available

May 2, 2012

The Babylonian Tower of Toxicology

Pharmacelsus publication in q&more

April 20, 2012

The Right Dose - Alternatives to animal experiments for the determination of acute toxicityq&more (01/2012, page 34).

Pharmacelsus Newsletter 04/2012

April 2, 2012

The second issue of the Pharmacelsus Newsletter (PDF) in 2012 provides our readers with the white paper "The Babylonian Tower of Toxicology".

New Pharmacelsus video available on Youtube

March 1, 2012

Please click here to view the Pharmacelsus video.

HepaTox Project completed

February 21, 2012

3D in vitro model for hepatic drug toxicity


German Red Cross thanks Pharmacelsus for the donation of a defibrillator

January 25, 2012

Pharmacelsus Newsletter 01/2012

January 16, 2012

Pharmacelsus strongly extended its capability and capacity - New high-class LCMS/MS system with Orbitrap technology (PDF).

Pharmacelsus' News Archive

Pharmacelsus' Newsletter Archive